SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

52.6 0.67

Rezumat

Modificarea prețului

24h

Curent

Minim

52.35

Maxim

52.9

Indicatori cheie

By Trading Economics

Venit

-57M

32M

Vânzări

199M

434M

P/E

Medie Sector

20.225

56.602

EPS

0.457

Randament dividend

2.15

Marjă de profit

7.411

Angajați

2,197

EBITDA

40M

138M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+48.38% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.15%

2.45%

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-643M

2.8B

Deschiderea anterioară

51.93

Închiderea anterioară

52.6

Sentimentul știrilor

By Acuity

50%

50%

177 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 19:39 UTC

Principalele dinamici ale pieței

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 mai 2025, 23:18 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mai 2025, 22:30 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- Update

16 mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mai 2025, 21:54 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mai 2025, 21:17 UTC

Top știri

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mai 2025, 20:55 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

16 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mai 2025, 20:37 UTC

Top știri

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mai 2025, 20:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mai 2025, 20:30 UTC

Achiziții, Fuziuni, Preluări

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mai 2025, 20:18 UTC

Top știri

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mai 2025, 20:16 UTC

Top știri

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mai 2025, 20:15 UTC

Câștiguri

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mai 2025, 20:11 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: William K. Daniel Joins Board

16 mai 2025, 20:10 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: Strategic Investment by KKR Completed

16 mai 2025, 20:05 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mai 2025, 18:51 UTC

Top știri

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mai 2025, 18:41 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 mai 2025, 18:35 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 18:32 UTC

Top știri

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

48.38% sus

Prognoză pe 12 luni

Medie 77.75 EUR  48.38%

Maxim 90 EUR

Minim 65.5 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

177 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.